Contents:

Introduction to Datamonitor TABLE OF CONTENTS EXECUTIVE SUMMARY Report summary Introduction Patient potential in prostate cancer Unmet needs in prostate cancer Investors in prostate cancer Class focus Future market leaders R&D opportunities in Prostate cancer DISEASE OVERVIEW AND DEFINITIONS Definition of disease Classification of disease Staging Hormone refractory prostate cancer Second-line patient treatment Risk factors Classification of pipeline products Hormonals Angiogenesis inhibitors Immunotherapies Cytotoxics Gene therapies Clinical endpoints in disease Disease progress PSA reduction Quality-of-life Multiple endpoints Unmet needs in disease Improved efficacy Hormone refractory prostate cancer Side effects Compliance PIPELINE ANALYSIS Pipeline analysis by development strategy Key drug discovery strategies in prostate cancer Key R&D protocol strategies in disease Key drug delivery strategies in disease Key licensing strategies in disease Pipeline analysis by class Pipeline analysis by region Pipeline analysis by company type Pipeline analysis by individual company DRUG ANALYSIS Overview of drug analysis Cytotoxics currently in late-stage development for prostate cancer Vinorelbine Suramin Apra CEP-701 Irofulven Rubitecan DX-8951f SR 48692 Immunotherapies currently in late-stage development for prostate cancer Provenge MDX210 Prostvac SGN-15 GVAX Prolog Mobista Onyvax Angiogenesis inhibitors currently in late stage development for prostate cancer Iressa Thalomid Prinomastat ABT627 Hormonals currently in late-stage development for prostate cancer Abarelix SPD 424 Cetrotide Promaxx 100 Gene therapies ISIS 3521 ISIS 5132 Leuvectin Genasense Other therapies Aptosyn Atragen Incel Perillyl alcohol Promising agents in phase I development Gonadimmune Neovastat Metastat SnET2 Recently discontinued projects SU101 Anti-VEGF Humanized Monoclonal Antibody BMS 182751 COMPARATIVE ANALYSIS Comparison by class Efficacy Side effects Hormone-refractory prostate cancer Comparative analysis of cytotoxics Comparison of satisfaction of unmet needs within the cytotoxic class Comparative analysis of immunotherapies Comparison of satisfaction of unmet needs within the immunotherapy class Comparative analysis of anti-angiogenesis agents Comparison of satisfaction of unmet needs within the anti-angiogenesis class Comparative analysis of hormonals Comparison of satisfaction of unmet needs within the hormonals class Comparative analysis of gene therapies Comparison of satisfaction of unmet needs within the gene therapy class Comparative analysis of 'others' FUTURE FOCUS Market drivers in prostate cancer Patent expiries New hormonal therapy launches New drug classes: angiogenesis inhibitors and gene therapies Price cuts in Japan Reformation of Medicare Factors affecting individual classes, 2000-2007 Future trends in the prevalence of prostate cancer Prospective drug launches in Prostate cancer Launch forecast methodology Forecast launches in Prostate cancer from 2000 to 2007 Prostate cancer market forecasts Forecast methodology Key R&D product forecasts Cytotoxic product forecasts Immunotherapy product forecasts Hormonal product forecasts Anti-angiogenesis product forecasts Gene therapy product forecasts Long term potential of phase I and pre-clinical compounds APPENDICES Research program methodology SPRINT databases SPRINT R&D; Primary Research Quantification of Data Reliability Strategic Issues and Opinion Surveys References LIST OF TABLES LIST OF FIGURES